243 related articles for article (PubMed ID: 35713517)
21. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
[TBL] [Abstract][Full Text] [Related]
22. PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.
Shi Q; Xuhong J; Luo T; Ge J; Liu F; Lan Y; Chen Q; Tang P; Fan L; Chen L; Liang Y; Wang M; Hu Y; Zhang Y; Bian X; Qi X; Jiang J
Br J Cancer; 2023 Jan; 128(1):121-129. PubMed ID: 36323880
[TBL] [Abstract][Full Text] [Related]
23. Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis.
Mao X; Lv P; Gong Y; Wu X; Tang P; Wang S; Zhang D; You W; Wang O; Zhou J; Li J; Jin F
Front Oncol; 2022; 12():855512. PubMed ID: 35463365
[TBL] [Abstract][Full Text] [Related]
24. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
[TBL] [Abstract][Full Text] [Related]
25. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
26. A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequential nab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer.
Yang JX; Yang YQ; Hu WY; Yang L; Wu J; Wen XX; Yu J; Huang ML; Xu DD; Tie DC; Wang L; Li FF; Li NL
Oncologist; 2024 Jan; 29(1):e15-e24. PubMed ID: 37279780
[TBL] [Abstract][Full Text] [Related]
27. Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.
Guarneri V; Griguolo G; Miglietta F; Conte PF; Dieci MV; Girardi F
ESMO Open; 2022 Apr; 7(2):100433. PubMed ID: 35276440
[TBL] [Abstract][Full Text] [Related]
28. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
[TBL] [Abstract][Full Text] [Related]
29. Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial.
Ye G; Chen P; Liu X; He T; Pivot X; Pan R; Zhou D; Zhu L; Zhang K; Li W; Yang S; Lin J; Cai G; Huang H
Gland Surg; 2024 Mar; 13(3):374-382. PubMed ID: 38601287
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer.
Uriarte-Pinto M; Escolano-Pueyo Á; Gimeno-Ballester V; Pascual-Martínez O; Abad-Sazatornil MR; Agustín-Ferrández MJ
Int J Clin Pharm; 2016 Apr; 38(2):446-53. PubMed ID: 26951122
[TBL] [Abstract][Full Text] [Related]
31. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.
Foldi J; Mougalian S; Silber A; Lannin D; Killelea B; Chagpar A; Horowitz N; Frederick C; Rispoli L; Burrello T; Abu-Khalaf M; Sabbath K; Sanft T; Brandt DS; Hofstatter EW; Hatzis C; DiGiovanna MP; Pusztai L
Breast Cancer Res Treat; 2018 Jun; 169(2):333-340. PubMed ID: 29396664
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study.
Liu L; Zhu M; Wang Y; Li M; Gu Y
World J Surg Oncol; 2023 Dec; 21(1):389. PubMed ID: 38114991
[TBL] [Abstract][Full Text] [Related]
33. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M
Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.
Gluz O; Nitz UA; Christgen M; Kuemmel S; Holtschmidt J; Schumacher J; Hartkopf A; Potenberg J; Lüedtke-Heckenkamp K; Just M; Schem C; von Schumann R; Kolberg-Liedtke C; Eulenburg CZ; Schinköthe T; Graeser M; Wuerstlein R; Kates RE; Kreipe HH; Harbeck N
JAMA Oncol; 2023 Jul; 9(7):946-954. PubMed ID: 37166817
[TBL] [Abstract][Full Text] [Related]
35. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
36. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
Xu B; Yan M; Ma F; Hu X; Feng J; Ouyang Q; Tong Z; Li H; Zhang Q; Sun T; Wang X; Yin Y; Cheng Y; Li W; Gu Y; Chen Q; Liu J; Cheng J; Geng C; Qin S; Wang S; Lu J; Shen K; Liu Q; Wang X; Wang H; Luo T; Yang J; Wu Y; Yu Z; Zhu X; Chen C; Zou J;
Lancet Oncol; 2021 Mar; 22(3):351-360. PubMed ID: 33581774
[TBL] [Abstract][Full Text] [Related]
37. Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study.
Li Q; Wang Y; Zhu M; Gu Y; Tang Y
Gland Surg; 2021 Dec; 10(12):3389-3402. PubMed ID: 35070899
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial.
Huang L; Chen S; Yang W; Xu B; Huang T; Yang H; Zheng H; Wang Y; Song E; Zhang J; Cui S; Pang D; Tang L; Lei Y; Geng C; Shao Z
Oncotarget; 2015 Jul; 6(21):18683-92. PubMed ID: 26084292
[TBL] [Abstract][Full Text] [Related]
39. A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.
A L-Tweigeri T; AlSayed A; Alawadi S; Ibrahim M; Ashour W; Jaafar H; Abulkhair O; A L-Abdulkarim H; Khalid H; Ajarim D;
Cancer Chemother Pharmacol; 2016 Jan; 77(1):147-53. PubMed ID: 26563257
[TBL] [Abstract][Full Text] [Related]
40. Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
Hanusch C; Schneeweiss A; Loibl S; Untch M; Paepke S; Kümmel S; Jackisch C; Huober J; Hilfrich J; Gerber B; Eidtmann H; Denkert C; Costa S; Blohmer JU; Engels K; Burchardi N; von Minckwitz G
Clin Cancer Res; 2015 Jul; 21(13):2924-31. PubMed ID: 25825476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
